MTHFD2 and Miyoshi myopathy: Based on the above results, we hypothesized that MTHFD2 may be associated with drug sensitivity to PIs, and subsequent assays demonstrated that targeting MTHFD2 has a significant synergistic anti-MM effect with bortezomib in vivo and in vitro.